Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus Clinical Trial

Official title:

A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00306384
• Other study ID #: SYR-322-OLE-012
• Secondary ID: 2005-004672-20U1
• Status: Completed
• Phase: Phase 3
• First received: March 21, 2006
• Last updated: February 17, 2013
• Start date: March 2006
• Est. completion date: November 2011

Study information

• Verified date: February 2013
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationBulgaria: Bulgarian Drug AgencyCzech Republic: State Institute for Drug ControlEstonia: The State Agency of MedicineLatvia: State Agency of MedicinesNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsRomania: National Medicines AgencyUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.

Description:

SYR-322 (alogliptin) is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes mellitus by prolonging the beneficial effects of glucagon-like peptide-1.

The rising incidence of type 2 diabetes mellitus and the limitations of the currently available treatments suggest the need for new therapies for glycemic control. Studies have been undertaken in humans that evaluated the effects of directly augmenting glucagon-like peptide-1 and glucose-dependent insulinotropic peptide levels and of inhibiting the activity of dipeptidyl peptidase IV.

This study is an extension of 7 controlled phase 3 studies of alogliptin. These phase 3 studies included 1 monotherapy study of alogliptin (SYR-322-PLC-010; NCT00286455); 4 placebo-controlled add-on studies of alogliptin, namely in combination with a sulfonylurea (SYR-322-SULF-007; NCT00286468), metformin (SYR-322-MET-008; NCT00286442), a thiazolidinedione (pioglitazone; SYR-322-TZD-009; NCT00286494), and insulin (SYR-322-INS-011; NCT00286429); 1 coadministration study with pioglitazone in combination with metformin (01-05-TL-322OPI-001; NCT00328627), and 1 coadministration study with pioglitazone (01-06-TL-322OPI-002; NCT00395512).

The end of treatment or early withdrawal visit from the preceding study will be the screening visit for this study, after which enrolled patients will be required to commit to approximately 22 additional visits at the study center.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3323
• Est. completion date: November 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

• Type 2 diabetes mellitus and was enrolled in one of the following 7 controlled Phase III studies. The study will be open to all patients who completed one of these studies through the end-of-treatment visit:

• SYR-322-PLC-010 - NCT00286455

• SYR-322-SULF-007 - NCT00286468

• SYR-322-MET-008 - NCT00286442

• SYR-322-TZD-009 - NCT00286494

• SYR-322-INS-011 - NCT00286429

• 01-05-TL-322OPI-001 - NCT00328627

• 01-06-TL-322OPI-002 - NCT00395512

• Alanine aminotransferase less than or equal to 3 times the upper limit of normal and serum creatinine less than or equal to 2.0 mg per dL.

• Able and willing to monitor own blood glucose concentrations with a home glucose monitor.

• No major illness or debility that in the investigator's opinion prohibits the patient from completing the study.

Exclusion Criteria

• The occurrence of any adverse event or condition during the controlled Phase III studies, which, in the opinion of the investigator, should exclude the patient from participating in the open-label extension.

• Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

• Weight-loss drugs

• Investigational antidiabetics, additional dipeptidyl peptidase-4 (DPP-4) and glucagon-like peptide-1 (GLP 1) inhibitors

• Incretin Mimetics,

• Oral or systemically injected glucocorticoids.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Drug:
• Alogliptin
Alogliptin tablets.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Chile,  Czech Republic,  Dominican Republic,  Germany,  Guatemala,  Netherlands,  Peru,  Poland,  South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)	Safety was assessed by physical examinations, clinical laboratory parameters, electrocardiogram (ECG) readings, vital sign measurements, oral temperature, and hypoglycemic events. Changes in laboratory values or ECG parameters were considered to be adverse events if they were judged to be clinically significant. A TEAE was any event that started on or after the first dose of open-label study drug and within 14 days after the last dose.	4 years	Yes
Secondary	Change From Baseline Over Time in Glycosylated Hemoglobin	The change from Baseline in glycosylated hemoglobin (HbA1c; the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) during the study. Endpoint was defined as the last postbaseline observation collected within 7 days after the last dose of open-label study drug.	Baseline and Month 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42 and 45.	No
Secondary	Change From Baseline in Fasting Plasma Glucose	The change from Baseline in fasting plasma glucose (FPG) at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.	Baseline and Year 4	No
Secondary	Percentage of Participants With Marked Hyperglycemia	Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (=11.10 mmol/L).; The Month 42 to Month 45 interval includes all marked hyperglycemic episodes occurring on or after Day 1247 (a 203-day visit window).	Randomization up to 4 years.	No
Secondary	Change From Baseline in Proinsulin Level	Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.; Note: A transcription error occurred in the reporting of 1 proinsulin value for a patient in the alogliptin 25 mg completed group, for whom a partial patient ID number was mistakenly entered as an end-of-treatment proinsulin level.	Baseline and Year 4	No
Secondary	Change From Baseline in Insulin Level	The change from Baseline in fasting insulin at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.	Baseline and Year 4	No
Secondary	Change From Baseline in C-peptide Level	C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.	Baseline and Year 4	No
Secondary	Change From Baseline in Body Weight	Change from Baseline in body weight to the last post-baseline observation collected within 7 days after the last dose of open-label study drug.	Baseline and Year 4	No
Secondary	Percentage of Participants With a Clinical Response	Clinical response was defined based on the absolute value of HbA1c meeting one of two clinical targets at any post-baseline visit: HbA1c =6.5%; HbA1c =7.0%.	Weeks 2, 4, 8, 12, every 3 months up to 4 years, and 1 Day after final dose.	No